Statistics from Altmetric.com
- Age-related macular degeneration
- corneal endothelium
- specular microscopy
- vascular endothelial growth factor-A
Ranibizumab (rhuFabV2, Lucentis; Genentech, San Francisco, California) is a humanised monoclonal antibody fragment, designed to bind all isoforms of human vascular endothelial growth factor-A (VEGF-A) by preventing the interaction of VEGF-A with its receptors VEGFR-1 (Flt-1) and VEGFR-2 (Flk-1/KDR).
Although the pharmacokinetic profile of ranibizumab after intravitreal injection in humans has not been determined definitively, ranibizumab has been detected in the aqueous humour after intravitreal standard injections in a rabbit model.1 Moreover, VEGF and its receptors were expressed in the corneal endothelium.2–5 Therefore, ranibizumab in the aqueous humour after intravitreal injections may affect the function of VEGF in the corneal endothelium, being potentially cytotoxic to human corneal endothelial cells. In the present study, we analyse the effect of the …
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.